Authors: Korenblat, Phillip E.; Rosenwasser, Lanny J.

Source: Allergy and Asthma Proceedings, Volume 31, Number 3, May/June 2010 , pp. 190-202(13)

Publisher: OceanSide Publications, Inc

Abstract:

The combination of budesonide and formoterol administered in one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) is approved in the United States in two dosage strengths (budesonide/formoterol pMDI 80/4.5 μg × 2 inhalations [160/9 μg] or 160/4.5 μg × 2 inhalations [320/9 μg]) in a fixed-dose, twice-daily regimen for the treatment of patients ≥12 years old with persistent asthma not adequately controlled with an inhaled corticosteroid (ICS) alone. This article reviews the clinical profile of budesonide/formoterol pMDI in patients with persistent asthma, including information on pharmacogenetics, efficacy, and tolerability. Studies of budesonide/formoterol pMDI in patients with asthma were identified through PubMed and respiratory meeting abstract databases. Budesonide/formoterol pMDI 160/9 μg has shown a rapid onset (within 15 minutes) of clinically significant bronchodilation that is faster than fluticasone propionate/salmeterol dry powder inhaler (DPI) 250/50 μg (within 30 minutes). The efficacy and tolerability profile of budesonide/formoterol pMDI 320/9 μg was similar to fluticasone propionate/salmeterol DPI 250/50 μg and budesonide/formoterol DPI 320/9 μg in adults and adolescents with persistent asthma. Short-term (12-week) and long-term (6- to 12-month) studies have established greater efficacy and similar tolerability of budesonide/formoterol pMDI compared with its monocomponents and placebo in patients with mild/moderate or moderate/severe persistent asthma. Studies evaluating patient-reported outcomes, including health-related quality of life and patient satisfaction with treatment, further support the benefits of budesonide/formoterol pMDI in patients with persistent asthma. In summary, budesonide/formoterol pMDI is an effective, well-tolerated treatment option for patients with persistent asthma for whom ICS/long-acting β₂-adrenergic agonist combination therapy is appropriate.

References: 64 references open in new window

Articles that cite this article?

Keywords: Budesonide; combination therapy; efficacy; formoterol; inhaled corticosteroid; long-acting beta2-adrenergic agonist; persistent asthma; pharmacology; pressurized metered-dose inhaler; safety

Document Type: Research article

DOI: http://dx.doi.org/10.2500/aap.2010.31.3356

Publication date: 2010-05-01

More about this publication?

• Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
  
  The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
  
  Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
  
  Articles marked "F" offer free full text for personal noncommercial use only.
  
  The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
• Editorial Board
• Information for Authors
• Submit a Paper
• Information for Advertisers
• Reprint Requests
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Allergy & Immunology
• By this author: Korenblat, Phillip E. ;  Rosenwasser, Lanny J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers